News
MRTX
58.70
-0.03%
-0.02
BUZZ-Bristol Myers hits over four-year low after co swings to loss
Shares of drugmaker Bristol Myers Squibb fall 7.50% to hit over four-year low of $45.20. Co posts Q1 loss of $4.40/shr. Company slashes annual profit outlook due to charges related to recent acquisitions.
Reuters · 1d ago
UPDATE 4-Bristol Myers posts quarterly loss, lays out $1.5 bln cost-saving plan
Bristol Myers Squibb posts quarterly loss, lays out $1.5 bln cost-saving plan. Charges related to acquisitions offset small increase in revenue, sending shares down 8%. The company also announced plans to save about $ 1.5 billion in costs by the end of 2025. Bristol's quarterly revenue rose 5% to $11.87 billion. Sales of older cancer drugs Opdivo and Revlimid fell.
Reuters · 1d ago
BUZZ-Bristol Myers falls as deal costs weigh on 2024 outlook
Shares of drugmaker Bristol Myers Squibb fall 1.5% to $48.14 premarket. Co slashes annual profit outlook to between 40 cents and 70 cents per share due to deal costs. Company posts first-quarter loss of $4.40 per share. Sales of cancer drug Opdivo miss estimates by $24 million.
Reuters · 1d ago
UPDATE 2-British billionaire Joe Lewis fined $5 million by US judge for insider trading
British billionaire Joe Lewis fined $5 million by US judge for insider trading. Lewis pleaded guilty in January to sharing illegal stock tips. The 87-year-old will serve three years of probation and pay a fine. Lewis is worth $6.2 billion, according to Forbes. Prosecutors said he passed on inside information on his portfolio companies.
Reuters · 04/04 19:49
Multibillionaire Joe Lewis to face US sentencing for insider trading
British multibillionaire Joe Lewis to face US sentencing for insider trading. Federal sentencing guidelines call for a prison sentence of up to two years. Prosecutors have urged leniency for the 87-year-old. Lewis admitted guilt in January to illegally sharing stock tips he gleaned from his investments.
Reuters · 04/04 15:31
Weekly Report: what happened at MRTX last week (0226-0301)?
Weekly Report · 03/04 09:14
Weekly Report: what happened at MRTX last week (0219-0223)?
Weekly Report · 02/26 09:16
Weekly Report: what happened at MRTX last week (0212-0216)?
Weekly Report · 02/19 09:16
Weekly Report: what happened at MRTX last week (0205-0209)?
Weekly Report · 02/12 09:15
Bristol Myers cut at Redburn as looming headwinds cloud buyouts
Redburn Atlantic downgrades Bristol-Myers Squibb to Neutral from Buy. Analyst says headwinds against established products offset any positive impact from recent buyouts. The downgrade comes as BMY increasingly turns to M&A as its blockbuster therapies face competition. BMY agreed to acquire Mirati Therapeutics in $20B deal.
Seeking Alpha · 02/06 13:19
Weekly Report: what happened at MRTX last week (0129-0202)?
Weekly Report · 02/05 09:16
Weekly Report: what happened at MRTX last week (0122-0126)?
Weekly Report · 01/29 09:15
Scotiabank Reaffirms Their Hold Rating on Mirati Therapeutics (MRTX)
TipRanks · 01/24 12:38
Mirati Therapeut: Statement of changes in beneficial ownership of securities
Press release · 01/24 06:05
More
Webull provides a variety of real-time MRTX stock news. You can receive the latest news about Mirati Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About MRTX
Mirati Therapeutics, Inc. is a commercial-stage oncology company. The Company is developing novel therapeutics to address the genetic and immunological promoters of cancer. The Company's product KRAZATI is an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Its MRTX1133 is an investigational, selective, and potent KRAS G12D inhibitor. Its MRTX1719 is an investigational synthetic lethal PRMT5 inhibitor designed to specifically target the PRMT5/ methylthioadensoine (MTA) complex. Its MRTX0902 is a potent, selective SOS1 inhibitor, designed to improve anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors. Its Sitravatinib is an investigational spectrum-selective kinase inhibitor designed to potently inhibit receptor tyrosine kinases (RTKs) and enhance immune responses through the inhibition of immunosuppressive signaling.